More than four years after Amgen’s cholesterol-lowering antibody Repatha was approved in the US, the company still can’t generate much sales momentum behind the product. Its latest gambit is to make ...
Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha (evolocumab) ...
We're celebrating 25 years of work to advance a bold vision for a just and inclusive democracy and economy that reflects a growing and diversifying nation. Read Taifa Smith Butler's reflection on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback